Literature DB >> 22221038

PARP1 polymorphisms increase the risk of gastric cancer in a Chinese population.

Wenting He1, Tao Liu, Yong Shan, Kexiang Zhu, Yumin Li.   

Abstract

BACKGROUND AND
OBJECTIVE: Poly(adenosine diphosphate [ADP]-ribose) polymerase 1 (PARP1), a protein involved in the DNA repair mechanism, plays an important role in carcinogenesis. In this study, we investigated whether single nucleotide polymorphisms of PARP1 contribute to gastric cancer (GC) and its precursor lesions (gastric precancerous lesions; GPL) in a case-control study conducted in the Hexi area of China, a high-risk area for GC.
METHODS: PARP1 162C>G (Phe54Leu) and 2819A>G (Lys940Arg) polymorphisms were genotyped by real-time PCR using a TaqMan assay in 140 GC cases, 110 GPL cases, and 120 controls. Data were statistically analyzed using the chi-squared test and a logistic regression model.
RESULTS: The presence of the PARP1 2819G allele was associated with an increased risk of GC (odds ratio [OR] 2.354; 95% CI 1.140, 4.861; p = 0.018), especially for cardia GC and diffuse-type GC (ORs 2.988 and 3.784, respectively). We also observed an interaction between Helicobacter pylori infection, GC family history, and the presence of the PARP1 2819G allele. In contrast, the PARP1 162C>G polymorphism was not significantly associated with GPL or GC.
CONCLUSION: The study suggests that the PARP1 2819G allele is associated with an increased risk of GC. In addition, H. pylori-positive status and family history jointly contribute to a higher risk of GC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221038     DOI: 10.1007/bf03256428

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  24 in total

1.  A prospective correlation of Laurén's histological classification of stomach cancer with clinicopathological findings including DNA flow cytometry.

Authors:  K H Lee; J H Lee; J K Cho; T W Kim; Y K Kang; J S Lee; W K Kim; J G Chung; I C Lee; H S Sun
Journal:  Pathol Res Pract       Date:  2001       Impact factor: 3.250

2.  Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma.

Authors:  Bingtao Hao; Haijian Wang; Kaixin Zhou; Yi Li; Xiaoping Chen; Gangqiao Zhou; Yunping Zhu; Xiaoping Miao; Wen Tan; Qingyi Wei; Dongxin Lin; Fuchu He
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

3.  DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation.

Authors:  Malka Cohen-Armon; Leonid Visochek; Dana Rozensal; Adi Kalal; Ilona Geistrikh; Rodika Klein; Sarit Bendetz-Nezer; Zhong Yao; Rony Seger
Journal:  Mol Cell       Date:  2007-01-26       Impact factor: 17.970

Review 4.  Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Authors:  Lata Chandi Thatai; Mousumi Banerjee; Zongshan Lai; Ulka Vaishampayan
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

Review 5.  Racial differences in lung cancer.

Authors:  Shirish M Gadgeel; Gregory P Kalemkerian
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

6.  The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.

Authors:  Kristin L Lockett; M Craig Hall; Jianfeng Xu; S Lilly Zheng; Marianne Berwick; Shu-Chun Chuang; Peter E Clark; Scott D Cramer; Kurt Lohman; Jennifer J Hu
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

7.  Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori.

Authors:  Carlos W Nossa; Prashant Jain; Batcha Tamilselvam; Vijay R Gupta; Lin-Feng Chen; Valérie Schreiber; Serge Desnoyers; Steven R Blanke
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

Review 8.  DNA damage response pathways in tumor suppression and cancer treatment.

Authors:  Yulong Liang; Shiaw-Yih Lin; F Charles Brunicardi; John Goss; Kaiyi Li
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

Review 9.  PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

Authors:  Andreína Peralta-Leal; José Manuel Rodríguez-Vargas; Rocío Aguilar-Quesada; María Isabel Rodríguez; José Luis Linares; Mariano Ruiz de Almodóvar; F Javier Oliver
Journal:  Free Radic Biol Med       Date:  2009-04-10       Impact factor: 7.376

10.  Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands.

Authors:  A C de Vries; G A Meijer; C W N Looman; M K Casparie; B E Hansen; N C T van Grieken; E J Kuipers
Journal:  Gut       Date:  2007-08-14       Impact factor: 23.059

View more
  5 in total

Review 1.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

2.  Expression of cluster of differentiation-95 and relevant signaling molecules in liver cancer.

Authors:  Xuming Wang; Kanglai Wei; Qiongguang Zhang; Sien Zeng; Jing Lin; Li Qiao; Lijiang Liu
Journal:  Mol Med Rep       Date:  2014-12-22       Impact factor: 2.952

3.  High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.

Authors:  Ying Liu; Yu Zhang; Ying Zhao; Dongna Gao; Jing Xing; Hui Liu
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

4.  Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.

Authors:  Wenxin Luo; Panwen Tian; Yue Wang; Heng Xu; Lu Chen; Chao Tang; Yang Shu; Shouyue Zhang; Zhoufeng Wang; Jun Zhang; Li Zhang; Lili Jiang; Lunxu Liu; Guowei Che; Chenglin Guo; Hong Zhang; Jiali Wang; Weimin Li
Journal:  Int J Cancer       Date:  2018-05-07       Impact factor: 7.396

5.  Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population.

Authors:  Maria Peña-Chilet; Maite Blanquer-Maceiras; Maider Ibarrola-Villava; Conrado Martinez-Cadenas; Manuel Martin-Gonzalez; Cristina Gomez-Fernandez; Matias Mayor; Juan Antonio Aviles; Ana Lluch; Gloria Ribas
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.